NeuroDerm, Ltd. Israel New Jersey

NeuroDerm Announces Publication of Positive Results from Phase 3 BouNDless Trial Evaluating ND0612 in Parkinson's Disease Patients with Motor Fluctuations

Data published in The Lancet Neurology showed favorable efficacy of ND0612 compared to oral immediate-release levodopa/carbidopaView original content:https://www.prnewswire.co.uk/news-releases/neuroderm-announces-publication-of-positive-results-from-phase-3-boundless-trial-evaluating-nd0612-in-parkinsons-disease-patients-with-motor-fluctuations-302091264.html